Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMalignant neoplasms of respiratory and intrathoracic organsICD-10-CM c39-malignant-neoplasm-other-ill-defined-sites
    Ask Trek AI about this page

    ICD-10-CM Code For Malignant Neoplasm Of Other And Ill-Defined Sites In The Respiratory System And Intrathoracic Organs: Group Overview

    The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code group C39 includes malignant neoplasms of other and ill-defined sites in the respiratory system and intrathoracic organs, covering cancers of structures like the heart, mediastinum, pleura, and unspecified intrathoracic locations. These ICD-10-CM diagnosis codes are used to document primary malignant tumors when the neoplasm site is specified as other or ill-defined within the respiratory and intrathoracic region, capturing organ involvement and diagnostic specificity. Accurate coding within the ICD-10-CM C39 group supports proper claim adjudication, complete clinical documentation, and appropriate reimbursement.

    Customize your policy alerts

    Sign up for ICD-10-CM Code For Malignant Neoplasm Of Other And Ill-Defined Sites In The Respiratory System And Intrathoracic Organs: Group Overview policy alerts

    Get alerted when relevant policies change without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    ICD-10-CM C39: Malignant Neoplasm Of Other And Ill-Defined Sites In The Respiratory System And Intrathoracic Organs Overview

    This code group represents malignant tumors located in respiratory and intrathoracic sites that are not otherwise specified or are described as ill-defined. It targets cancers arising in areas such as the heart, mediastinum, pleura, and other contiguous intrathoracic structures. Accurate coding matters for complete clinical records and supports appropriate reimbursement and claim processing.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    When to Use

    Use a code from this group when a primary malignant neoplasm is documented in an intrathoracic site that is described as other specified or ill-defined within the respiratory and intrathoracic region. Select the most specific code available that reflects the documented site and diagnostic information in the clinical record.

    ICD-10-CM Codes

    2 rows

    ICD-10-CM CodeDescription
    C39.0Malignant neoplasm of upper respiratory tract, part unspecified
    C39.9Malignant neoplasm of lower respiratory tract, part unspecified

    DRG Codes

    9 rows

    DRG CodeDescription
    011Tracheostomy for Face, Mouth and Neck Diagnoses or Laryngectomy with MCC
    012Tracheostomy for Face, Mouth and Neck Diagnoses or Laryngectomy with CC
    013Tracheostomy for Face, Mouth and Neck Diagnoses or Laryngectomy without CC/MCC
    146Ear, Nose, Mouth and Throat Malignancy with MCC
    147Ear, Nose, Mouth and Throat Malignancy with CC
    148Ear, Nose, Mouth and Throat Malignancy without CC/MCC
    180Respiratory Neoplasms with MCC
    181Respiratory Neoplasms with CC
    182Respiratory Neoplasms without CC/MCC

    Typical Clinical Scenarios

    • An elderly patient with progressive dyspnea, chest pain, and unexplained weight loss is found on chest CT to have an irregular intrathoracic mass involving the superior mediastinum that cannot be clearly localized to lung, pleura, or trachea. Biopsy confirms a poorly differentiated malignant neoplasm arising in an intrathoracic organ with uncertain primary site, prompting assignment of a code for malignant neoplasm of other and ill-defined sites in the respiratory and intrathoracic organs. Typical codes: C39.9.
    • A middle-aged smoker presents to the emergency department with sudden onset hemoptysis and acute respiratory distress; imaging shows a centrally located mass at the thoracic inlet causing airway compromise and endobronchial bleeding, but the exact anatomic origin is indeterminate on initial evaluation. Because the malignancy is within the respiratory or intrathoracic region but not clearly attributable to a specific structure, an ill-defined site code from this group is used pending further workup. Typical codes: C39.0, C39.9.
    • A patient with known metastatic disease to intrathoracic soft tissues develops progressive dysphagia and superior vena cava syndrome; tumor involvement is documented in intrathoracic tissues that are not part of the lung, pleura, or trachea and is described as malignant neoplasm of other intrathoracic sites on pathology. In this chronic complication/comorbidity setting, a code for malignant neoplasm of other and ill-defined intrathoracic sites is assigned to capture the intrathoracic tumor location. Typical codes: C39.0, C39.9.

    Related Codes

    C30-MALIGNANT-NEOPLASM-NASAL-CAVITY-MIDDLE-EAR

    ICD-10-CM Code For Malignant Neoplasm Of Nasal Cavity And Middle Ear: Group Overview

    C31-MALIGNANT-NEOPLASM-ACCESSORY-SINUSES

    ICD-10-CM Code For Malignant Neoplasm Of Accessory Sinuses: Group Overview

    C32-MALIGNANT-NEOPLASM-OF-LARYNX

    ICD-10-CM Code For Malignant Neoplasm Of Larynx: Group Overview

    C33-MALIGNANT-NEOPLASM-OF-TRACHEA

    ICD-10-CM Code For Malignant Neoplasm Of Trachea: Group Overview

    C34-MALIGNANT-NEOPLASM-OF-BRONCHUS-AND-LUNG

    ICD-10-CM Code For Malignant Neoplasm Of Bronchus And Lung: Group Overview

    C37-MALIGNANT-NEOPLASM-OF-THYMUS

    ICD-10-CM Code For Malignant Neoplasm Of Thymus: Group Overview

    C38-MALIGNANT-NEOPLASM-HEART-MEDIASTINUM-PLEURA

    ICD-10-CM Code For Malignant Neoplasm Of Heart Mediastinum And Pleura: Group Overview

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.